CAM-PAC

Integrative Analysis of Gene Functions in Cellular and Animal Models of Pancreatic Cancer

 Coordinatore PHILIPPS UNIVERSITAET MARBURG 

 Organization address address: Biegenstrasse 10
city: MARBURG
postcode: 35032

contact info
Titolo: Ms.
Nome: Lois
Cognome: Woestman
Email: send email
Telefono: +49 6421 2824919
Fax: +49 642128 26382

 Nazionalità Coordinatore Germany [DE]
 Totale costo 14˙691˙298 €
 EC contributo 11˙193˙108 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-IP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-11-01   -   2018-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    PHILIPPS UNIVERSITAET MARBURG

 Organization address address: Biegenstrasse 10
city: MARBURG
postcode: 35032

contact info
Titolo: Ms.
Nome: Lois
Cognome: Woestman
Email: send email
Telefono: +49 6421 2824919
Fax: +49 642128 26382

DE (MARBURG) coordinator 1˙507˙350.00
2 POLYGENE AG CH participant 1˙366˙700.00
3    QUEEN MARY UNIVERSITY OF LONDON

 Organization address address: 327 MILE END ROAD
city: LONDON
postcode: E1 4NS

contact info
Titolo: Mr.
Nome: Reuben
Cognome: Almeida
Email: send email
Telefono: +44 20 7882 6038
Fax: +44 20 7882 7276

UK (LONDON) participant 1˙298˙221.50
4    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

 Organization address address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675

contact info
Titolo: Ms.
Nome: Beate
Cognome: Schaulin
Email: send email
Telefono: +49 89 4140 2856
Fax: +49 89 4140 4926

DE (MUENCHEN) participant 1˙290˙000.00
5    UNIVERSITA DEGLI STUDI DI VERONA

 Organization address address: VIA DELL ARTIGLIERE 8
city: VERONA
postcode: 37129

contact info
Titolo: Dr.
Nome: Enrico Maria
Cognome: Cazzaroli
Email: send email
Telefono: +39 045 8126446
Fax: +39 045 8126446

IT (VERONA) participant 1˙148˙400.00
6    Nome Ente NON disponibile

 Organization address address: Rosenhof 1
city: Heilbad Heiligenstadt
postcode: 37308

contact info
Titolo: Mr.
Nome: Ulrich
Cognome: Marschall
Email: send email
Telefono: +49 3606 671 0
Fax: +49 3606 671 200

DE (Heilbad Heiligenstadt) participant 921˙287.00
7    UNIVERSITAET ULM

 Organization address address: HELMHOLTZSTRASSE 16
city: ULM
postcode: 89081

contact info
Titolo: Ms.
Nome: Michaela
Cognome: Schuhmacher
Email: send email
Telefono: +49 731 50 25049
Fax: +49 731 50 25068

DE (ULM) participant 805˙800.00
8    CEGAT GMBH

 Organization address address: PAUL EHRLICH STRASSE 17
city: TUBINGEN
postcode: 72076

contact info
Titolo: Dr.
Nome: Stefan
Cognome: Ohrnberger
Email: send email
Telefono: +49 7071 565 44 20
Fax: +49 07071 565 44 22

DE (TUBINGEN) participant 800˙071.00
9    EXPERIMENTELLE PHARMAKOLOGIE UND ONKOLOGIE BERLIN-BUCH GMBH

 Organization address address: ROBERT-ROESSLE-STRASSE 10
city: BERLIN
postcode: 13125

contact info
Titolo: Dr.
Nome: Diana
Cognome: Behrens
Email: send email
Telefono: +49 3094063862
Fax: +49 0394063823

DE (BERLIN) participant 765˙000.00
10 Concentris Research Management GmbH DE participant 499˙500.00
11    UNIVERSITEIT LEIDEN

 Organization address address: RAPENBURG 70
city: LEIDEN
postcode: 2300 RA

contact info
Titolo: Mr.
Nome: Ton
Cognome: Brouwer
Email: send email
Telefono: +31 71 527 3149
Fax: 31715275269

NL (LEIDEN) participant 490˙000.00
12    MIMETAS BV

 Organization address address: ANKERSTRAAT 29
city: DEN HAAG
postcode: 2586 RH

contact info
Titolo: Dr.
Nome: Jos
Cognome: Joore
Email: send email
Telefono: +31 6 516 96 884

NL (DEN HAAG) participant 300˙000.00
13    FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

 Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3
city: MADRID
postcode: 28029

contact info
Titolo: Ms.
Nome: Dolores
Cognome: Liébanes
Email: send email
Telefono: +34 917328000 4033

ES (MADRID) participant 778.44
14    MEDICAL DELTA MULTIPLIER BV

 Organization address address: MARCONISTRAAT 16
city: ROTTERDAM
postcode: 3029 AK

contact info
Titolo: Mr.
Nome: Martin
Cognome: Luxemburg
Email: send email
Telefono: 31654902237

NL (ROTTERDAM) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

genetic    data    tissues    genes    cam    disease    dismal    pac    alterations    transcriptomic    treatments    scientists    academic    metabolic    impact    animal    cellular    cancer    multiple    patients    cells    treatment    clinical    molecular    survival    accumulation    models    integrate    tumor    directly    identification    cancers    pdac    therapeutic    affected    human    pancreatic    functions    tumors    integrative    addition    intervention    healthy    despite    malignant    gene   

 Obiettivo del progetto (Objective)

'Cancers are genetic disease arising from the accumulation of multiple molecular alterations in affected cells. Large-scale genomic, transcriptomic and proteomic analyses have established comprehensive catalogues of molecules which are altered in their structure and/or abundance in malignant tumors as compared to healthy tissues. Far less developed are concepts and methods to integrate data from different sources and to directly interrogate gene functions on a large scale in order to differentiate “driver” alterations, which directly contribute to tumor progression, from indolent “passenger” alterations. As a consequence, examples of successful translation of knowledge generated from “omics” approaches into novel clinical concepts and applications are scarce. Pancreatic cancer is a prime example of this dilemma. Representing the 4th to 5th most common cause of cancer related deaths, it is a disease with a major socioeconomic impact. Despite enormous advances in the identification of molecular changes associated with the disease, new treatment options have not emerged. Thus, 5-year survival rates remain unchanged at a dismal 6%, the lowest for all solid tumors. Using pancreatic cancer as a model disease, the goal of this integrative project is to develop novel cellular and animal models, as well as novel strategies to generate, analyze and integrate large scale metabolic and transcriptomic data from these models, in order to systematically characterize and validate novel targets for therapeutic intervention. In addition to the general tumor cell population, special consideration will be given to sub-populations of tumor-initiating cells, a.k.a. tumor stem cells. To this end, the consortium comprises i) SMEs with strong focus on technology development, ii) clinical and academic partners with extensive experience in pancreatic cancer molecular biology and management of pancreatic cancer patients, and iii) technology and data analysis experts from academic groups.'

Introduzione (Teaser)

Cancer arises from the accumulation of multiple molecular alterations. To develop novel treatments we need to understand how malignant cells differ at the molecular level from their healthy counterparts.

Descrizione progetto (Article)

Pancreatic ductal adenocarcinoma (PDAC) ranks amongst the most common cancers and has very dismal prognosis with a five year survival rate of only 6 %. It is virtually resistant to any conventional therapeutic regimens. Despite advances in the identification of molecular alterations in PDAC very little of this knowledge has been translated into novel treatments.

The EU-funded http://www.cam-pac.eu/ (CAM-PAC) (Integrative analysis of gene functions in cellular and animal models of pancreatic cancer) project aims to identify novel targets for therapeutic intervention and develop bioinformatic models for predictive diagnostics. The consortium will develop novel cellular and animal models of the disease and perform a large-scale analysis of metabolic, transcriptomic and genetic data from these models.

The generated cellular and animal tools will carry modifications in certain target genes to assess affected signalling pathways. Systematic functional characterisation of target genes relies on novel technologies for temporal and spatial control of transgene expression. Scientists will identify the functions of these genes and monitor their impact on tumourigenicity. So far, a central growth-regulatory role of many of the selected target genes has been demonstrated in vitro.

In addition to these experimental models of PDAC, the project will analyse primary human tissues at the molecular level. To address the inter- and intra-tumour heterogeneity in human PDAC, scientists will also use xenografts from patient samples.

The findings of the study are anticipated to contribute to a better understanding of the disease, identify new compounds and therapeutic targets for PDAC. Considering the annual increase of PDAC incidence, innovative diagnostic and treatment approaches are urgently needed to prolong survival and reduce the suffering of pancreatic cancer patients.

Altri progetti dello stesso programma (FP7-HEALTH)

NANOTEST (2008)

Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics

Read More  

EUROBIOFORUM II (2011)

International forum for European life sciences funders and performers

Read More  

NMTRYPI (2014)

New Medicines for Trypanosomatidic Infections

Read More